Cargando…
BEX1 acts as a tumor suppressor in acute myeloid leukemia
Acute myeloid leukemia (AML) is a heterogeneous disease of the myeloid lineage. About 35% of AML patients carry an oncogenic FLT3 mutant making FLT3 an attractive target for treatment of AML. Major problems in the development of FLT3 inhibitors include lack of specificity, poor response and developm...
Autores principales: | Lindblad, Oscar, Li, Tianfeng, Su, Xianwei, Sun, Jianmin, Kabir, Nuzhat N., Levander, Fredrik, Zhao, Hui, Lu, Gang, Rönnstrand, Lars, Kazi, Julhash U. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673273/ https://www.ncbi.nlm.nih.gov/pubmed/26046670 |
Ejemplares similares
-
FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia
por: Chougule, Rohit A., et al.
Publicado: (2016) -
The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
por: Moharram, Sausan A., et al.
Publicado: (2019) -
Correction: The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
por: Moharram, Sausan A., et al.
Publicado: (2019) -
Src-like adaptor protein 2 (SLAP2) binds to and inhibits FLT3 signaling
por: Moharram, Sausan A., et al.
Publicado: (2016) -
Src-Like Adaptor Protein (SLAP) Binds to the Receptor Tyrosine Kinase Flt3 and Modulates Receptor Stability and Downstream Signaling
por: Kazi, Julhash U., et al.
Publicado: (2012)